TY - JOUR
T1 - Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction
AU - Gehlken, Carolin
AU - Screever, Elles M.
AU - Suthahar, Navin
AU - van der Meer, Peter
AU - Westenbrink, B. Daan
AU - Coster, Jennifer E.
AU - Van Veldhuisen, Dirk J.
AU - de Boer, Rudolf A.
AU - Meijers, Wouter C.
N1 - Funding Information:
Dr. Meijers was supported by the Mandema Stipendium from the Junior Scientific Masterclass (MA 20-04). Dr. de Boer was supported by the Netherlands Heart Foundation (Hartstichting) (CVON DOSIS, Grant 2014-40; CVON SHE-PREDICTS-HF, Grant 2017-21; and CVON RED-CVD, Grant 2017-11), the Innovational Research Incentives Scheme programme of the Netherlands Organization for Scientific Research (Nationaal Regieorgaan Praktijkgericht Onderzoek SIA) (NWO VIDI, Grant 917.13.350), and the H2020 European Research Council (ERC CoG 818715, SECRETE-HF). We would like to thank our colleagues for their logistic support with this study and especially mention Martje van der Wal, Astrid Koops, Kuna S. van Dijk, and Janke Warink-Riemersma.
Funding Information:
Dr. Meijers was supported by the Mandema Stipendium from the Junior Scientific Masterclass (MA 20‐04). Dr. de Boer was supported by the Netherlands Heart Foundation (Hartstichting) (CVON DOSIS, Grant 2014‐40; CVON SHE‐PREDICTS‐HF, Grant 2017‐21; and CVON RED‐CVD, Grant 2017‐11), the Innovational Research Incentives Scheme programme of the Netherlands Organization for Scientific Research (Nationaal Regieorgaan Praktijkgericht Onderzoek SIA) (NWO VIDI, Grant 917.13.350), and the H2020 European Research Council (ERC CoG 818715, SECRETE‐HF).
Publisher Copyright:
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
PY - 2021/8
Y1 - 2021/8
N2 - Aims: Two key echocardiographic parameters that are currently used to diagnose heart failure (HF) with preserved ejection fraction (HFpEF) are left atrial volume index (LAVi) and left ventricular mass index (LVMi). We investigated whether patients' characteristics, biomarkers, and co-morbidities are associated with these parameters and whether the relationships differ between patients with HFpEF or HF with reduced ejection fraction (HFrEF). Methods: We consecutively enrolled 831 outpatients with typical signs and symptoms of HF and elevated N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels and categorized patients based upon left ventricular ejection fraction (LVEF): LVEF < 40% (HFrEF), LVEF between 40% and 50% (HF with mid-range ejection fraction), and LVEF ≥ 50% (HFpEF). The study includes consecutively enrolled HF patients from an HF outpatient clinic at a tertiary medical centre in the Netherlands. All patients underwent baseline characterization, laboratory measurements, and echocardiography. Results: Four hundred sixty-nine patients had HFrEF, 189 HF with mid-range ejection fraction, and 173 HFpEF. The patients with HFrEF were rather male [HFrEF: 323 (69%); HFpEF: 80 (46%); P < 0.001], and the age was comparable (HFrEF 67 ± 13; HFpEF 70 ± 14; P = 0.069). In HFpEF, more patients had hypertension [190 (40.5%); 114 (65.9%); P < 0.001], higher body mass indices (27 ± 8; 30 ± 7; P < 0.001), and atrial fibrillation [194 (41.4); 86 (49.7); P = 0.029]. The correlation analyses showed that in HFrEF patients, LAVi was significantly associated with age (β 0.293; P < 0.001), male gender (β 0.104; P = 0.042), body mass index (β −0160; P = 0.002), diastolic blood pressure (β −0.136; P < 0.001), New York Heart Association (β 0.174; P = 0.001), atrial fibrillation (β 0.381; P < 0.001), galectin 3 (β 0.230; P < 0.001), NT-proBNP (β 0.183; P < 0.001), estimated glomerular filtration rate (β −0.205; P < 0.001), LVEF (β −0.173; P = 0.001), and LVMi (β 0.337; P < 0.001). In HFpEF patients, only age (β 0.326; P < 0.001), atrial fibrillation (β 0.386; P < 0.001), NT-proBNP (β 0.176; P = 0.036), and LVMi (β 0.213; P = 0.013) were associated with LAVi. Conclusions: Although LVMi and LAVi are hallmark parameters to diagnose HFpEF, they only correlate with a few characteristics of HF and mainly with atrial fibrillation. In contrast, in HFrEF patients, LAVi relates strongly to several other HF parameters. These findings underscore the complexity in visualizing the pathophysiology of HFpEF and question the relation between cardiac structural remodeling and the impact of co-morbidities.
AB - Aims: Two key echocardiographic parameters that are currently used to diagnose heart failure (HF) with preserved ejection fraction (HFpEF) are left atrial volume index (LAVi) and left ventricular mass index (LVMi). We investigated whether patients' characteristics, biomarkers, and co-morbidities are associated with these parameters and whether the relationships differ between patients with HFpEF or HF with reduced ejection fraction (HFrEF). Methods: We consecutively enrolled 831 outpatients with typical signs and symptoms of HF and elevated N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels and categorized patients based upon left ventricular ejection fraction (LVEF): LVEF < 40% (HFrEF), LVEF between 40% and 50% (HF with mid-range ejection fraction), and LVEF ≥ 50% (HFpEF). The study includes consecutively enrolled HF patients from an HF outpatient clinic at a tertiary medical centre in the Netherlands. All patients underwent baseline characterization, laboratory measurements, and echocardiography. Results: Four hundred sixty-nine patients had HFrEF, 189 HF with mid-range ejection fraction, and 173 HFpEF. The patients with HFrEF were rather male [HFrEF: 323 (69%); HFpEF: 80 (46%); P < 0.001], and the age was comparable (HFrEF 67 ± 13; HFpEF 70 ± 14; P = 0.069). In HFpEF, more patients had hypertension [190 (40.5%); 114 (65.9%); P < 0.001], higher body mass indices (27 ± 8; 30 ± 7; P < 0.001), and atrial fibrillation [194 (41.4); 86 (49.7); P = 0.029]. The correlation analyses showed that in HFrEF patients, LAVi was significantly associated with age (β 0.293; P < 0.001), male gender (β 0.104; P = 0.042), body mass index (β −0160; P = 0.002), diastolic blood pressure (β −0.136; P < 0.001), New York Heart Association (β 0.174; P = 0.001), atrial fibrillation (β 0.381; P < 0.001), galectin 3 (β 0.230; P < 0.001), NT-proBNP (β 0.183; P < 0.001), estimated glomerular filtration rate (β −0.205; P < 0.001), LVEF (β −0.173; P = 0.001), and LVMi (β 0.337; P < 0.001). In HFpEF patients, only age (β 0.326; P < 0.001), atrial fibrillation (β 0.386; P < 0.001), NT-proBNP (β 0.176; P = 0.036), and LVMi (β 0.213; P = 0.013) were associated with LAVi. Conclusions: Although LVMi and LAVi are hallmark parameters to diagnose HFpEF, they only correlate with a few characteristics of HF and mainly with atrial fibrillation. In contrast, in HFrEF patients, LAVi relates strongly to several other HF parameters. These findings underscore the complexity in visualizing the pathophysiology of HFpEF and question the relation between cardiac structural remodeling and the impact of co-morbidities.
KW - Biomarkers
KW - Echocardiography
KW - Heart failure with preserved ejection fraction (HFpEF)
KW - Left atrial volume index (LAVi)
KW - Left ventricular mass index (LVMi)
KW - NT-proBNP
U2 - 10.1002/ehf2.13366
DO - 10.1002/ehf2.13366
M3 - Article
C2 - 34085774
AN - SCOPUS:85107155763
SN - 2055-5822
VL - 8
SP - 2458
EP - 2466
JO - ESC Heart Failure
JF - ESC Heart Failure
IS - 4
ER -